Incyte announces European Commission Approval of Pemazyre (R) (Pemigatinib) for the Treatment of Adults with locally advanced or metastatic Cholangiocarcinoma and Fusions or Rearrangements in the Fibroblast Growth Factor Receptor-2 (FGFR2) Gene-MedSci.cn

Incyte announces European Commission Approval of Pemazyre (R) (Pemigatinib) for the Treatment of Adults with locally advanced or metastatic Cholangiocarcinoma and Fusions or Rearrangements in the Fibroblast Growth Factor Receptor-2 (FGFR2) Gene

[Anonymous]

ONCOLOGY RESEARCH AND TREATMENT, 2021; 44 (5):

科室
- - 订阅+
  - 更多科室
工具
服务